ReviewCNS drugs2024
Impulse Control Disorders in Parkinson's Disease: An Overview of Risk Factors, Pathogenesis and Pharmacological Management.
Review in CNS drugs, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- From Tradition to Innovation: Acupuncture Therapies Targeting Ferroptosis in Neurological Disorders.Brain and behavior · 2025Pooled it
- Long-Term Clinical Efficacy, Safety, and Polypharmacy Simplification of Levodopa-Entacapone-Carbidopa Intestinal Gel in Advanced Parkinson's Disease: An 18-Month Longitudinal Study.Journal of clinical medicine · 2026Article
- The Effect of Dopaminergic Medication on Impulse Control and Compulsive Behaviour: A Translational Perspective.Basic & clinical pharmacology & toxicology · 2026Review
- Reflexive eye movement alterations are related to subclinical impulsive-compulsive behaviors in Parkinson's disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Relationships between perceived social support, self-efficacy, coping styles and resilience in older patients with Parkinson's disease.BMC geriatrics · 2026Article
- Serotonergic cortico-limbic and executive network dysfunction in Parkinson's disease impulse control disorders: a PET-fMRI study.NPJ Parkinson's disease · 2026Article
- Association of Impulse Control Disorders with Cognitive Performance and Frontal Dysfunction in Patients with Parkinson's Disease.Journal of clinical medicine · 2026Article
- Therapeutic Spectrum of Intermittent Apomorphine in Parkinson's Disease: Neuropsychiatric, Behavioral, and Cognitive Analyses.Noro psikiyatri arsivi · 2026Article
- A transdiagnostic approach to non-motor symptoms in Parkinson's disease: exploring internalizing, bipolar spectrum, and impulsive compulsive behavior profiles via cluster analysis.Frontiers in aging neuroscience · 2026Article
- Neuropsychological aspects of impulse control disorders in Parkinson's disease.Frontiers in aging neuroscience · 2026Review
- Electrophysiological Signatures of Planned and Unplanned Continuous Movement Termination in Parkinson's Disease.eNeuro · 2025Article
- Validation of the Turkish Version of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (Quip-Rs).Psychiatry and clinical psychopharmacology · 2025Article
- Recognition, management, and patient perspectives of impulsive-compulsive disorders in Parkinson's disease.Journal of Parkinson's disease · 2025Article
- Behavioral disorders in Parkinson disease: current view.Journal of neural transmission (Vienna, Austria : 1996) · 2025Review
- From cigarettes to compulsions: a longitudinal study in de novo Parkinson's disease.Frontiers in psychology · 2025Article
- Neuropsychiatric disorders in Parkinson's disease.Therapeutic advances in neurological disorders · 2025Review
- Optimized use of safinamide as an add-on therapy in Asian patients with Parkinson's disease: a narrative review and expert opinion.Therapeutic advances in neurological disorders · 2025Review
- No association between genetically predicted vitamin D levels and Parkinson's disease.PloS one · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Impulse control disorders in Parkinson's disease are relatively common drug-induced addictive behaviours that are usually triggered by the dopamine agonists pramipexole, ropinirole and rotigotine. This narrative review aimed to provide a comprehensive overview of the current knowledge of impulse control disorders in Parkinson's disease. We summarised the prevalence, clinical features, risk factors and potential underlying mechanisms of impulse control disorders in Parkinson's disease. Moreover, recent advances in behavioural and imaging characteristics and management strategies are discussed. Early detection as well as a tailored multidisciplinary approach, which typically includes careful adjustment of the dopaminergic therapy and the treatment of associated neuropsychiatric symptoms, are necessary. In some cases, a continuous delivery of levodopa via a pump or the dopamine D
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.